In these highly immunogenic “hot” tumours, where there is infiltration and subsequent silencing of T cells by tumour cells, anti-PD-1/PD-L1 immune checkpoint blockades (ICBs) have been highly effective therapies [6]. Here, PDCD1 is linked to neoplasm.